Vistagen Appoints Elissa Cote as Chief Development Officer

VistaGen Therapeutics ( (VTGN) ) has provided an announcement.

On June 25, 2025, Vistagen Therapeutics announced the appointment of Elissa Cote as Chief Corporate Development Officer, effective June 23, 2025. Ms. Cote, with nearly 30 years of experience in biopharmaceuticals, will lead strategic opportunities to advance Vistagen’s pherine platform and cultivate partnerships. Her appointment is seen as pivotal for Vistagen’s growth, as she brings expertise in business development and strategic transactions, which are crucial for the company’s future commercial launches and partnerships.

The most recent analyst rating on (VTGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

Spark’s Take on VTGN Stock

According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.

VistaGen Therapeutics’ overall stock score is primarily impacted by its financial challenges and weak technical indicators. However, ongoing developments in clinical trials and recent corporate actions provide some optimism for future growth. The stock remains a high-risk investment due to current financial and operational hurdles.

To see Spark’s full report on VTGN stock, click here.

More about VistaGen Therapeutics

Vistagen is a late clinical-stage biopharmaceutical company based in South San Francisco, CA, specializing in the development and commercialization of intranasal product candidates called pherines. These products are designed to activate nose-to-brain neurocircuits without requiring systemic absorption, offering potential therapeutic benefits for conditions such as social anxiety disorder and major depressive disorder.

Average Trading Volume: 146,145

Technical Sentiment Signal: Sell

Current Market Cap: $60.94M

Find detailed analytics on VTGN stock on TipRanks’ Stock Analysis page.